Safety and efficacy of Cellular Matrix™, PRP-HA for the management of tibiofemoral knee osteoarthritis

“Cellular matrix™ PRP-HA”: A new treatment option with platelet-rich plasma and hyaluronic acid for patients with osteoarthritis having had an unsatisfactory clinical response to hyaluronic acid alone: Results of a pilot, multicenter French study with long-term follow-up

Article specifications

This clinical trial was published in 2018 in Journal of Int. J. Clin. Rheumatol. (IF 2017/2018: 0.08) by French specialists. The purpose of this review was to evaluate the safety and efficacy of Cellular Matrix™, a new medical device designed for one-step preparation of platelet-rich plasma in presence of hyaluronic acid, for the management of tibiofemoral knee osteoarthritis in patients who had failed to respond adequately to previous treatment with hyaluronic acid alone.

 

Results

A 3-injection course of a combination of platelet-rich plasma and hyaluronic acid prepared with Cellular Matrix was well tolerated and effective in the long-term to relieve pain associated with symptomatic knee osteoarthritis.

Interestingly, longterm evaluation demonstrated that this treatment was still effective for at least 2 years for 50% of the patients that completed our survey and allowed avoiding surgery for almost 80% of them. Cellular Matrix technology may therefore represent a new medical alternative to knee surgery after failure of HA or, at least, a viable strategy allowing to delay the need for joint replacement surgery